FDA Wants To Be “Model” Agency: Preparing For Clinical Trial Simulations
Executive Summary
FDA plans to make greater use of mathematical and statistical models to guide drug development and approval decisions, Center for Drug Evaluation & Research Scientific Advisor Donald Stanski said Oct. 5 at a R&D conference sponsored by Phacilitate in Geneva, Switzerland
You may also be interested in...
FDA “Critical Path” May Lead To Changes In Dosing, Active-Control Trials
FDA's "Critical Path" drug development initiative will explore relaxing the agency's interpretation of active-control trials, Office of Medical Policy Director Robert Temple, MD, said
FDA “Critical Path” May Lead To Changes In Dosing, Active-Control Trials
FDA's "Critical Path" drug development initiative will explore relaxing the agency's interpretation of active-control trials, Office of Medical Policy Director Robert Temple, MD, said
Biomarker Working Group To Explore Development Of Guidance
An FDA working group will be formed by year-end to consider the development of a guidance on biomarkers